PI
ACAD icon

Putnam Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Putnam Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$3.2M Buy
102,262
+16,859
+20% +$403K ﹤0.01% 623
2023
Q3 		$1.78M Buy
85,403
+4,923
+6% +$134K ﹤0.01% 746
2023
Q2 		$1.93M Buy
80,480
+55,157
+218% +$1.23M ﹤0.01% 738
2023
Q1 		$477K Sell
25,323
-1,067
-4% -$20.3K ﹤0.01% 949
2022
Q4 		$420K Sell
26,390
-14
-0.1% -$219 ﹤0.01% 974
2022
Q3 		$432K Buy
+26,404
New +$428K ﹤0.01% 966
2020
Q3 		– Sell
-74,844
Closed -$3.63M – 823
2020
Q2 		$3.63M Buy
74,844
+5,132
+7% +$246K 0.01% 521
2020
Q1 		$2.94M Buy
69,712
+6,541
+10% +$270K 0.01% 533
2019
Q4 		$2.7M Buy
+63,171
New +$2.75M 0.01% 687
2017
Q2 		– Sell
-13,178
Closed -$454K – 1101
2017
Q1 		$454K Sell
13,178
-3,469
-21% -$122K ﹤0.01% 1118
2016
Q4 		$480K Buy
16,647
+286
+2% +$7.57K ﹤0.01% 1124
2016
Q3 		$521K Sell
16,361
-21,835
-57% -$740K ﹤0.01% 1120
2016
Q2 		$1.24M Sell
38,196
-41,110
-52% -$1.38M ﹤0.01% 1065
2016
Q1 		$2.22M Buy
79,306
+13,548
+21% +$295K 0.01% 921
2015
Q4 		$2.34M Sell
65,758
-1,523
-2% -$53.7K 0.01% 933
2015
Q3 		$2.23M Buy
67,281
+2,039
+3% +$84.8K 0.01% 964
2015
Q2 		$2.73M Sell
65,242
-484
-0.7% -$18.7K 0.01% 959
2015
Q1 		$2.14M Sell
65,726
-2,451
-4% -$84.2K ﹤0.01% 1038
2014
Q4 		$2.16M Sell
68,177
-380
-0.6% -$10.8K ﹤0.01% 1004
2014
Q3 		$1.7M Buy
68,557
+1,277
+2% +$29.9K ﹤0.01% 1067
2014
Q2 		$1.52M Buy
67,280
+87
+0.1% +$1.82K ﹤0.01% 1100
2014
Q1 		$1.63M Sell
67,193
-98,171
-59% -$2.48M ﹤0.01% 1091
2013
Q4 		$4.13M Sell
165,364
-154,929
-48% -$3.66M 0.01% 826
2013
Q3 		$8.8M Sell
320,293
-36,707
-10% -$767K 0.02% 475
2013
Q2 		$6.48M Buy
+357,000
New +$4.92M 0.02% 571

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Putnam Investments's ACAD Position: Q4 2023 in Review

Putnam Investments increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q4 2023, buying an estimated $403K and bringing the position to 102,262 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #623.

Putnam Investments first reported a position in ACAD in Q2 2013 and has held it in 25 quarters since. The position peaked at $8.8M in Q3 2013. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

  • Putnam Investments held 102,262 shares of Acadia Pharmaceuticals worth $3.2M as of Q4 2023.
  • Putnam Investments bought 16,859 Acadia Pharmaceuticals shares in Q4 2023, an estimated $403K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #623 holding.
  • Putnam Investments first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
  • Putnam Investments's Acadia Pharmaceuticals position peaked at $8.8M in Q3 2013.
  • 276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.